The most commonly reported side effects of diflunisal include fatigue, nausea, and drug hypersensitivity, based on 808 FDA adverse event reports from 2004 to 2025. 4.3% of reports found the drug to be ineffective.
Percentages show how often each reaction appears relative to total reports for diflunisal.
These are voluntary reports and do not establish that diflunisal caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside diflunisal. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
58.8% of diflunisal adverse event reports involve female patients and 26.0% involve male patients. The largest age group is adult at 55%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking diflunisal when the adverse event was reported.
Showing 15 of 56 indications
Diflunisal is sold under the brand name Dolobid.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.